ADJUBIL: A phase II study of immunotherapy with durvalumab and tremelimumab in combination with capecitabine or without capecitabine in adjuvant situation for biliary tract cancer

• Published in: Journal of clinical oncology Vol. 42; no. 3_suppl; p. TPS583
• Main Authors: Eickhoff, Regina, Pons, Miriam, Kochen, Lisa, Vortmeyer, Doerthe, Al-Batran, Salah-Eddin, Habibzade, Timursah, Adler, Marius, Gonzalez-Carmona, Maria A, Ettrich, Thomas Jens, Koehne, Claus-Henning, Pink, Daniel, van Boemmel, Florian, Pession, Ursula, Wehler, Thomas, Modest, Dominik Paul
• Format: Journal Article
• Language: English
• Published: American Society of Clinical Oncology 20.01.2024

TPS583Background: Despite improvements in multidisciplinary healthcare, patients with biliary tract cancer (BTC) have a poor outcome and effective treatment options are limited. Only 20 % of patients are eligible for surgical resection with curative intent, with 5-year overall survival rates < 10...